News

Verve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drug
Verve Therapeutics (VERV) stock surged as promising trial data for cholesterol therapy VERVE-102 prompted Cantor Fitzgerald ...
U.S. government made the wrong decision about chip exports, says Cantor Fitzgerald's CJ Muse
C.J. Muse, Cantor Fitzgerald analyst, joins CNBC's 'Squawk on the Street' to discuss how chip stocks are being impacted by new export controls.
Stagflation is 'best case scenario' in near-term, says Cantor Fitzgerald's Eric Johnston
Eric Johnston, Cantor Fitzgerald chief equity & macro strategist, joins 'Closing Bell Overtime' to talk economic and market impact of tariffs.
Meta Platforms price target lowered to $624 from $790 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Meta Platforms (META) to $624 from $790 and keeps an Overweight rating on the shares. The ...
Cantor Fitzgerald Sticks to Their Buy Rating for Nvidia (NVDA)
Cantor Fitzgerald analyst C J Muse reiterated a Buy rating on Nvidia (NVDA – Research Report) yesterday and set a price target of $200.00.Stay ...
Long Island Press1d
Jim Avena, former Manorhaven mayor, dies at 81
Jim Avena, former president of Cantor Fitzgerald and former mayor of Manorhaven, died on Sunday, April 13 at the age of 81.
Howard Lutnick’s no good, very bad weekend
He was proven very wrong on Monday as the stock dropped to $217.41 within 45 minutes of the market opening, according to ...
Yahoo Finance6d
Summit co-CEO option exercise ‘quite bullish,’ says Cantor Fitzgerald
Cantor Fitzgerald views Bob Duggan’s, Summit Therapeutics (SMMT) co-CEO and Chairman, stock option exercise “quite unusual” and “quite bullish” for the shares. Duggan’ exercised ...
Investing2d
Cantor Fitzgerald maintains overweight rating on Health Catalyst stock
On Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Health Catalyst Inc. (NASDAQ:HCAT) with a steady price target of $16.00. According to InvestingPro data, this target represents ...